According to the WHO's draft list of possible vaccines for the novel coronavirus, 198 different vaccines are being developed in various countries.
Of the vaccines, 156 have been going through a preclinical evaluation and 42 others a clinical evaluation. Ten of them have been undergoing Phase 3 trials which are the late-stage clinical trials and determine both the efficacy and safety of the vaccine.
Novavax, Johnson & Johnson, Moderna, Pfizer AstraZeneca, Sinovac, Sinopharm, and the Murdoch Children's Research Institute have been ahead in the race for final approval for their vaccines.
The candidature of the Globe Biotech vaccine has been shown on the WHO list as a DNA plasmid type vaccine at the preclinical stage.
In a press release, Globe Biotech said it is the only company, globally, to be listed with three vaccine candidates – DNA plasmid vaccine, Adenovirus Type 5 Vector and D614G variant LNP-encapsulated mRNA.
Earlier, the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) announced it would hold a human trial of BANCOVID, a Covid-19 vaccine developed by Globe Biotech.
On Wednesday, icddr,b signed a memorandum of understanding with the company to conduct the trial.
On 2 July, Globe Biotech announced it was developing a Covid-19 vaccine as it had completed preliminary animal trials successfully.
On 5 October, it said they had received "very promising" results from the pre-clinical trials on rabbits and mice.
The company said BANCOVID would hit the market in late December or early January next year if the government is fully supportive.
However, experts have expressed surprise at the Globe's claim.
"Do they have a magic wand? Will they ready the vaccine by December just by its touch?" asked Dr Muniruddin Ahmed, a professor at the Department of Clinical Pharmacy and Pharmacology of the University of Dhaka.
"It is October now. How will it be possible to complete three-stage trials of the vaccine, data collection and analyses, plus a peer review in an international journal in just two months? How can this claim be termed scientifically correct?" he added.
The clinical trial is very lengthy, critical and important as well, he added.
"We hope the Globe Biotech's initiative to develop a [novel] coronavirus vaccine sees success. But it is not possible to do so through exaggeration and unrealistic claims," he commented.